
ABOUT AMBRYSCORE

AmbryScore is a blood or saliva based prostate cancer marker (PCM) that helps patients with a family history of certain types of cancer determine if they may be at increased risk of having developed or eventually developing prostate cancer due to certain inherited, genetic variants. These results may help your health care provider fine tune your overall screening or treatment plan.



AmbryScore

HOW IT'S USED

- Ambry Score is known as a polygenic risk score (PRS), which means it can evaluate the genetic variants a man inherited at birth, as well as their age and ethnicity, to determine that individual's risk of having developed or risk of eventually developing prostate cancer.
- Available as add-on to one of Ambry's multi-gene panels, such as ProstateNext

INDICATIONS FOR USE

- Men of Northern European Ancestry with a personal and/or family history of any of the following:
 - Early-onset (<50) or metastatic prostate cancer,
 - >1 person with prostate, pancreatic, breast, or ovarian cancers
- No personal or family history of a mutation in a prostate cancer susceptibility gene, including ATM, BRCA1, BRCA2, CHEK2, EPCAM, HOXB13, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, RAD51D, TP53

SCIENCE

PRS is computed by assessing the patient's risk across 72 SNPs, compared to the SNP-effects reported in large prostate cancer studies

PRESENTATION OF RESULTS

Test results for AmbryScore are presented in the following fashion:

- Unaffected males (no current prostate cancer diagnosis):
 - Average remaining lifetime risk for prostate cancer (0-10.2%)
 - Above average remaining lifetime risk for prostate cancer (>10.2%)
- Affected males (current prostate cancer diagnosis):
 - Average PRS Score (≤ 1)
 - Above average PRS Score (>1)

COMPANY CONTACT

www.ambrygen.com/ 949-900-5500